Literature DB >> 12775574

Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo.

Shuiping Jiang1, Niels Camara, Giovanna Lombardi, Robert I Lechler.   

Abstract

Although CD4+CD25+ regulatory T cells are pivotal in the prevention of autoimmunity and appear to mediate transplantation tolerance, little is known concerning their antigen specificity. Here we describe the induction of a human CD4+CD25+ regulatory T-cell line specific for a defined peptide alloantigen (human leukocyte antigen A2 [HLA-A2] 138-170) by priming purified CD4+CD25+ cells ex vivo. The regulatory cells were anergic and retained their ability to suppress antigen-driven responses of CD4+CD25- cells. They inhibited not only interleukin 2 (IL-2) secretion by CD4+CD25- T cells specific for the same peptide but also direct alloresponse of naive CD4+CD25- T cells stimulated by semiallogeneic dendritic cells (DCs) in the presence of the peptide ("linked suppression"). They also suppressed the response of CD4+ T cells specific for viral and bacterial antigens. The suppressive T-cell line showed sustained high CD25 expression. These findings suggest that peripheral CD4+CD25+ regulatory cells are a precommitted cell lineage from which cells with specificity for non-self-peptides can be selected. This may pave the way for inducing and expanding peptide antigen-specific regulatory T cells ex vivo for cell therapy in transplantation, allergy, and autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775574     DOI: 10.1182/blood-2003-04-1164

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

Review 1.  CD4+ CD25+ Treg: divide and rule?

Authors:  Lucy S K Walker
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

2.  De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells.

Authors:  Mindi R Walker; Bryan D Carson; Gerald T Nepom; Steven F Ziegler; Jane H Buckner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 3.  Regulatory T cells in human disease and their potential for therapeutic manipulation.

Authors:  Leonie S Taams; Donald B Palmer; Arne N Akbar; Douglas S Robinson; Zarin Brown; Catherine M Hawrylowicz
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

4.  Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells.

Authors:  S Alice Long; Jane H Buckner
Journal:  J Autoimmun       Date:  2008-03-03       Impact factor: 7.094

5.  Impaired CD4+CD25+ regulatory T cell activity in the peripheral blood of patients with autoimmune sensorineural hearing loss.

Authors:  Ming Xia; Han Bing Zhang; Fang Liu; Hai Ying Yin; An Ting Xu
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-01-22       Impact factor: 2.503

Review 6.  Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells.

Authors:  Paul L Bollyky; Ben A Falk; Rebecca P Wu; Jane H Buckner; Thomas N Wight; Gerald T Nepom
Journal:  J Leukoc Biol       Date:  2009-04-28       Impact factor: 4.962

Review 7.  The T-cell receptor repertoire of regulatory T cells.

Authors:  Rafal Pacholczyk; Joanna Kern
Journal:  Immunology       Date:  2008-12       Impact factor: 7.397

Review 8.  Regulatory T-cell therapy in transplantation: moving to the clinic.

Authors:  Qizhi Tang; Jeffrey A Bluestone
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

9.  Regulatory T cells in renal disease.

Authors:  Yuan Min Wang; Min Hu; Ya Wang; Tania Polhill; Geoff Yu Zhang; Yiping Wang; Vincent W S Lee; David C H Harris; Stephen I Alexander
Journal:  Int J Clin Exp Med       Date:  2008-08-20

10.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.